A First-In-Human Study to Evaluate Safety, Tolerability, Reactogenicity, and Immunogenicity of JNJ-64300535, a DNA Vaccine, Administered by Electroporation-Mediated Intramuscular Injection, in Participants With Chronic Hepatitis B Who Are on Stable Nucleos(t)Ide Therapy and Virologically Suppressed
CompletedNCT03463369
Janssen Sciences Ireland UCHepatitis B, Chronic
Start: 2018-04-18End: 2021-03-23Updated: 2021-04-14